馬丁·什克雷利（Martin Shkreli）爆炸了FDA生物製度評估與研究中心（CBER）的新負責人Vinay Prasad，作為“堅果”

這不是投資建議。作者在提到的任何股票中都沒有立場。 WCCFTECH.com有披露和道德政策。

Martin Shkreli, the former hedge fund manager who was once dubbed the most hated C-suite executive in America for massively hiking the price of a life-saving drug, is known for his proclivity to comment on all things pharma-related.

馬丁·什克雷利（Martin Shkreli）是前對沖基金經理，他曾被稱為美國最討厭的C-Suite高管，因為他大量遠足了挽救生命的藥物的價格，他以對與藥物有關的所有事物發表評論而聞名。

In keeping with this, Shkreli has just landed a few hard-hitting punches against the new head of FDA’s Center for Biologics Evaluation and Research (CBER), Vinay Prasad.

為此，Shkreli剛剛對FDA生物學評估與研究中心（CBER）的新負責人（Vinay Prasad）進行了一些艱苦的拳頭。

The only "emergency" America still faces with covid-19 is that regulators like Peter Marks are either incompetent or corrupt to authorize a booster without clinical, randomized data.https://t.co/EByJciOSGI

美國唯一與Covid-19的“緊急情況”是，彼得·馬克（Peter Marks）這樣的監管機構是無能或腐敗的，可以授權助推器，而沒有臨床，隨機數據。 https：//t.co/ebyjciosgi

— Vinay Prasad MD MPH (@VPrasadMDMPH) August 22, 2024

-Vinay Prasad MD MPH（@vprasadmdph）2024年8月22日

For the benefit of those who might not be aware, Prasad is an oncologist who has made a name for himself by vehemently opposing COVID-19 booster shots.

為了那些可能不知道的人的好處，普拉薩德是一位腫瘤學家，他通過強烈反對的Covid-19助推器射擊為自己而聞名。

In a recent blog post, Prasad diligently argued in favor of additional randomized trials for COVID-19 booster shots before updating the current inoculation recommendations.

在最近的博客文章中，普拉薩德（Prasad）勤奮地爭辯說，在更新當前的接種建議之前，支持了COVID-19-19的其他隨機試驗。

I have talked to the heads of almost ever single one of big pharma in the last 72 hours and he has no idea what is like out there. NONE! And Prasad has NO IDEA what it’s like out there. My people have been in this game for 25 years and they’re LOSING THEIR JOBS and these firms…

在過去的72個小時中，我已經與幾乎一個大型製藥公司的單身人士交談，他不知道那裡是什麼樣的。沒有任何！ Prasad不知道那裡的情況。我的人民從事這個遊戲已有25年了，他們正在失去工作和這些公司……

— Martin Shkreli (@MartinShkreli) May 5, 2025

- Martin Shkreli（@martinshkreli）2025年5月5日

This brings us to the crux of the matter. Martin Shkreli has now jumped into the growing controversy around Prasad’s appointment by asserting that the new head of the CBER is “nuts,” and has “no idea” about the ground realities of the nation’s pharma landscape.

這使我們進入了問題的癥結。馬丁·什克雷利（Martin Shkreli）現在涉及普拉薩德（Prasad）任命的越來越多的爭議，稱新的CBER負責人是“堅果”，並且對美國製藥景觀的基礎現實“不知道”。

Martin Shkreli asserts that he has been in touch with the “heads of almost ever[y] single one of big pharma in the last 72 hours,” and that these firms are “gonna go out of business.”

馬丁·什克雷利（Martin Shkreli）斷言，他一直與“過去72小時的大型製藥公司（Big Pharma）幾乎擁有過的單身人士”與他們保持聯繫，並且這些公司“會倒閉”。

Basically, Martin Shkreli thinks that Vinay Prasad will institute a more meticulous testing and trial regime at the CBER, which would strangle many of the pharma firms already contending with an increasingly competitive landscape and escalating job losses.

基本上，馬丁·什克雷利（Martin Shkreli）認為，Vinay Prasad將在CBER進行更細緻的測試和試驗制度，這將扼殺許多已經與競爭日益激烈的景觀競爭併升級工作損失的製藥公司。

As an illustration of this evolving paradigm, consider the fact that Bristol Myers Squibb (BMS) announced the layoff of 516 employees in April 2025, bringing its total layoffs so far this year to 806. Do note that BMS also shed 2,200 jobs in 2024.

為了說明這一不斷發展的範式，考慮到布里斯托爾·邁爾斯·索斯（Bristol Myers Squibb）（BMS）在2025年4月宣布了516名員工的裁員，今年到目前為止，其總裁員達到806。

Of course, some would view Martin Shkreli’s criticism of Vinay Prasad as a badge of honor of sorts - an indication that the new head of the CBER is not beholden to corporate interests. Yet, others might interpret this volley as an SOS for a besieged industry.

當然，有些人會將馬丁·什克雷利（Martin Shkreli）對Vinay Prasad的批評視為一種榮譽的徽章，這表明CBER的新負責人並不注視著公司利益。但是，其他人可能將這個凌空作解釋為被包圍行業的SOS。

Do you agree with Martin Shkreli’s criticism of Vinay Prasad? Is it not the very ethos of capitalism that the fittest firms should survive and struggling ones perish? Let us know your thoughts in the comments section below.

您是否同意馬丁·什克雷利（Martin Shkreli）對Vinay Prasad的批評？最優勝心的企業應該生存並掙扎的人滅亡，這不是資本主義的精神嗎？在下面的評論部分中讓我們知道您的想法。